Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.84
NUVA's Cash to Debt is ranked higher than
62% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. NUVA: 0.84 )
NUVA' s 10-Year Cash to Debt Range
Min: 0.51   Max: No Debt
Current: 0.84

Equity to Asset 0.49
NUVA's Equity to Asset is ranked higher than
57% of the 446 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. NUVA: 0.49 )
NUVA' s 10-Year Equity to Asset Range
Min: 0.36   Max: 0.93
Current: 0.49

0.36
0.93
Interest Coverage 1.22
NUVA's Interest Coverage is ranked lower than
58% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 235.10 vs. NUVA: 1.22 )
NUVA' s 10-Year Interest Coverage Range
Min: 1.22   Max: 9999.99
Current: 1.22

1.22
9999.99
F-Score: 6
Z-Score: 2.91
M-Score: -2.96
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 1.15
NUVA's Operating margin (%) is ranked higher than
68% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 5.91 vs. NUVA: 1.15 )
NUVA' s 10-Year Operating margin (%) Range
Min: -27436.54   Max: 6.71
Current: 1.15

-27436.54
6.71
Net-margin (%) -2.43
NUVA's Net-margin (%) is ranked higher than
64% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 4.15 vs. NUVA: -2.43 )
NUVA' s 10-Year Net-margin (%) Range
Min: -27211.54   Max: 16.37
Current: -2.43

-27211.54
16.37
ROE (%) -3.03
NUVA's ROE (%) is ranked higher than
64% of the 443 Companies
in the Global Medical Devices industry.

( Industry Median: 5.20 vs. NUVA: -3.03 )
NUVA' s 10-Year ROE (%) Range
Min: -322.04   Max: 21.43
Current: -3.03

-322.04
21.43
ROA (%) -1.50
NUVA's ROA (%) is ranked higher than
66% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. NUVA: -1.50 )
NUVA' s 10-Year ROA (%) Range
Min: -768.33   Max: 10.76
Current: -1.5

-768.33
10.76
ROC (Joel Greenblatt) (%) 2.87
NUVA's ROC (Joel Greenblatt) (%) is ranked higher than
68% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 9.15 vs. NUVA: 2.87 )
NUVA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -737.95   Max: 17.53
Current: 2.87

-737.95
17.53
Revenue Growth (3Y)(%) 11.70
NUVA's Revenue Growth (3Y)(%) is ranked higher than
86% of the 340 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. NUVA: 11.70 )
NUVA' s 10-Year Revenue Growth (3Y)(%) Range
Min: -40.2   Max: 486.2
Current: 11.7

-40.2
486.2
EBITDA Growth (3Y)(%) 12.10
NUVA's EBITDA Growth (3Y)(%) is ranked higher than
85% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 1.60 vs. NUVA: 12.10 )
NUVA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 22.7
Current: 12.1

0
22.7
EPS Growth (3Y)(%) -53.80
NUVA's EPS Growth (3Y)(%) is ranked higher than
53% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. NUVA: -53.80 )
NUVA' s 10-Year EPS Growth (3Y)(%) Range
Min: -66.3   Max: 31
Current: -53.8

-66.3
31
» NUVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

NUVA Guru Trades in Q4 2013

Louis Moore Bacon 25,000 sh (New)
Mario Gabelli 115,700 sh (+27.56%)
Jim Simons 261,788 sh (+14.93%)
Vanguard Health Care Fund 1,628,303 sh (unchged)
PRIMECAP Management 914,000 sh (unchged)
Joel Greenblatt Sold Out
Ken Fisher 367,150 sh (-3.29%)
Steven Cohen 482,285 sh (-16.69%)
Paul Tudor Jones 11,600 sh (-37.63%)
» More
Q1 2014

NUVA Guru Trades in Q1 2014

Jim Simons 346,527 sh (+32.37%)
Mario Gabelli 125,700 sh (+8.64%)
PRIMECAP Management 914,000 sh (unchged)
Vanguard Health Care Fund 1,628,303 sh (unchged)
Louis Moore Bacon Sold Out
Ken Fisher 361,300 sh (-1.59%)
Steven Cohen 405,000 sh (-16.02%)
Paul Tudor Jones 8,800 sh (-24.14%)
» More
Q2 2014

NUVA Guru Trades in Q2 2014

Paul Tudor Jones 13,082 sh (+48.66%)
Mario Gabelli 155,700 sh (+23.87%)
Steven Cohen 437,000 sh (unchged)
Vanguard Health Care Fund 1,628,303 sh (unchged)
Jim Simons 344,488 sh (-0.59%)
PRIMECAP Management 906,000 sh (-0.88%)
Ken Fisher 336,395 sh (-6.89%)
» More
Q3 2014

NUVA Guru Trades in Q3 2014

Louis Moore Bacon 130,000 sh (New)
Ken Fisher 1,177,679 sh (+250.09%)
Paul Tudor Jones 23,301 sh (+78.11%)
Steven Cohen 565,500 sh (+29.41%)
Mario Gabelli 166,700 sh (+7.06%)
Vanguard Health Care Fund 1,628,303 sh (unchged)
PRIMECAP Management 902,100 sh (-0.43%)
Jim Simons 126,288 sh (-63.34%)
» More
» Details

Insider Trades

Latest Guru Trades with NUVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2014-09-30 Add 250.09%0.06%$32.48 - $38.215 $ 47.3733%1177679
Mario Gabelli 2014-06-30 Add 23.87%0.01%$32.26 - $39.25 $ 47.3738%155700
Joel Greenblatt 2013-12-31 Sold Out 0.06%$24.07 - $33.52 $ 47.3757%0
Mario Gabelli 2013-12-31 Add 27.56%$24.07 - $33.52 $ 47.3757%115700
Mario Gabelli 2013-09-30 Add 49.42%$22.82 - $26.99 $ 47.3793%90700
Joel Greenblatt 2013-06-30 Reduce -38.01%0.05%$19.93 - $24.79 $ 47.37116%67093
Mario Gabelli 2013-06-30 Add 32.82%$19.93 - $24.79 $ 47.37116%60700
Joel Greenblatt 2013-03-31 Add 37.81%0.03%$15.46 - $21.31 $ 47.37160%108240
Mario Gabelli 2013-03-31 Add 42.81%$15.46 - $21.31 $ 47.37160%45700
Ken Fisher 2013-03-31 Reduce -23.45%$15.46 - $21.31 $ 47.37160%355475
Joel Greenblatt 2012-12-31 New Buy0.07%$12.65 - $23.01 $ 47.37225%78542
Ken Fisher 2012-12-31 Add 34.48%0.01%$12.65 - $23.01 $ 47.37225%464375
Mario Gabelli 2012-12-31 Add 88.24%$12.65 - $23.01 $ 47.37225%32000
PRIMECAP Management 2012-12-31 Add 34.88%$12.65 - $23.01 $ 47.37225%669000
Ken Fisher 2012-09-30 New Buy0.02%$19.61 - $25.71 $ 47.37112%345302
Mario Gabelli 2012-03-31 Add 21.43%$11.35 - $17.56 $ 47.37227%17000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.60
NUVA's P/B is ranked higher than
72% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. NUVA: 3.60 )
NUVA' s 10-Year P/B Range
Min: 0.98   Max: 10.93
Current: 3.6

0.98
10.93
P/S 3.00
NUVA's P/S is ranked higher than
73% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 3.57 vs. NUVA: 3.00 )
NUVA' s 10-Year P/S Range
Min: 0.86   Max: 10.64
Current: 3

0.86
10.64
PFCF 32.60
NUVA's PFCF is ranked higher than
87% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. NUVA: 32.60 )
NUVA' s 10-Year PFCF Range
Min: 6.98   Max: 188.94
Current: 32.6

6.98
188.94
EV-to-EBIT 267.55
NUVA's EV-to-EBIT is ranked higher than
70% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 61.55 vs. NUVA: 267.55 )
NUVA' s 10-Year EV-to-EBIT Range
Min: -2590.2   Max: 484
Current: 267.55

-2590.2
484
Current Ratio 3.72
NUVA's Current Ratio is ranked higher than
79% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.79 vs. NUVA: 3.72 )
NUVA' s 10-Year Current Ratio Range
Min: 1.58   Max: 15.05
Current: 3.72

1.58
15.05
Quick Ratio 2.78
NUVA's Quick Ratio is ranked higher than
78% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.01 vs. NUVA: 2.78 )
NUVA' s 10-Year Quick Ratio Range
Min: 1.14   Max: 13.9
Current: 2.78

1.14
13.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.60
NUVA's Price/Tangible Book is ranked higher than
73% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 6.92 vs. NUVA: 5.60 )
NUVA' s 10-Year Price/Tangible Book Range
Min: 2.36   Max: 34.31
Current: 5.6

2.36
34.31
Price/DCF (Projected) 2.30
NUVA's Price/DCF (Projected) is ranked higher than
86% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. NUVA: 2.30 )
NUVA' s 10-Year Price/DCF (Projected) Range
Min: 1.21   Max: 25.15
Current: 2.3

1.21
25.15
Price/Median PS Value 0.90
NUVA's Price/Median PS Value is ranked higher than
82% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. NUVA: 0.90 )
NUVA' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 2.83
Current: 0.9

0.3
2.83
Earnings Yield (Greenblatt) 0.40
NUVA's Earnings Yield (Greenblatt) is ranked higher than
68% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. NUVA: 0.40 )
NUVA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 4.8
Current: 0.4

0.2
4.8

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:NK8.Germany,
Nuvasive Inc. was incorporated in Delaware on July 21, 1997, and began commercializing its products in 2001. It is a medical device company engaged in developing minimally disruptive surgical products and procedures for the spine. The Company's current-marketed product portfolio is engaged in applications for spine fusion surgery, including biologics. The Company's product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS. The MAS platform combines three categories of solutions that collectively minimize soft tissue disruption during spine fusion surgery, provide maximum visualization and are designed to enable safe and reproducible outcomes for the surgeon and the patient. The platform includes its proprietary software-driven nerve detection and avoidance systems, NVM5 and NVJJB, and Intra-Operative Monitoring (IOM) support; MaXcess, an integrated split-blade retractor system; and a variety of specialized implants. The Company's primary business model is to loan its MAS systems to surgeons and hospitals who purchase implants, biologics and disposables for use in individual procedures. In addition, for larger customers, the Company's proprietary nerve monitoring systems, MaXcess and surgical instrument sets are placed with hospitals for an extended period at no up-front cost to them. The Company also offers a range of bone allograft in patented saline packaging, disposables and spine implants, which include its branded CoRoent products and fixation devices such as rods, plates and screws. Implants, biologics and disposables are shipped from the Company's inventories. The Company sells an immaterial quantity of MAS instrument sets, MaXcess and nerve monitoring systems to hospitals. Its spine surgery product line offerings, which include products for the thoracolumbar and the cervical spine, are used to enable access to the spine and to perform restoration and fusion procedures in a minimally disruptive fashion. In the United States, it currently sells its products through a combination of exclusive independent sales agencies and directly-employed sales shareowners. The Company has 230 issued U.S. patents, 165 foreign national patents, and 284 pending patent applications. The Company's competitors are Medtronic Sofamor Danek (Medtronic), DePuy/Synthes, a Johnson & Johnson company, Stryker Spine, Globus Medical, Biomet Spine, and Zimmer Spine. It also faces competition from physician owned distributorships (PODs), which are medical device distributors that are owned, directly or indirectly, by physicians. The Company's products,medical devices and tissues subject to regulation by the FDA and other regulatory bodies.
» More Articles for NUVA

Headlines

Articles On GuruFocus.com
NuVasive(R) Demonstrates Expanding EMEA Business at Eurospine 2014 With Surgeon Workshops and Innova Oct 15 2014 
Guru Fisher Cuts NUVA - Medical Insurance Resists NuVasive Procedure Apr 11 2013 
NuVasive Inc. (NUVA) President and COO Keith Valentine sells 2,015 Shares Jan 25 2011 
Weekly Guru Bargains Highlights: ASIA , SAY , VRX , AMLN , NUVA Jan 09 2011 
Weekly Guru Bargains Highlights: ASIA, SAY, VRX, AMLN, NUVA Jan 01 2011 
Three Stocks for 2011: NUVA, ENOC, CBK Nov 25 2010 
NuVasive Inc. Reports Operating Results (10-Q) Nov 05 2010 
NuVasive Inc. Reports Operating Results (10-Q) Aug 06 2010 
NuVasive Inc. (NUVA) CEO and Chairman Alexis V Lukianov sells 5,000 Shares Jul 12 2010 
NuVasive Inc. (NUVA) President and COO Keith Valentine sells 5,000 Shares Jun 22 2010 

More From Other Websites
Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 Dec 24 2014
NuVasive to Participate in Investor Events in December 2014 Nov 24 2014
NuVasive to Participate in Investor Events in December 2014 Nov 24 2014
NuVasive (NUVA) Flagged As Strong On High Volume Nov 17 2014
NuVasive (NUVA) Shares March Higher, Can It Continue? Nov 14 2014
NuVasive(R) Focused on Surgeon Support and Showcasing Industry-Leading Products at North American... Nov 10 2014
NuVasive(R) Focused on Surgeon Support and Showcasing Industry-Leading Products at North American... Nov 10 2014
NUVASIVE INC Financials Nov 06 2014
NuVasive to Host Investor Morning on November 13, 2014 Nov 03 2014
NuVasive to Host Investor Morning on November 13, 2014 Nov 03 2014
10-Q for NuVasive, Inc. Nov 01 2014
NuVasive reports 3Q loss Oct 30 2014
NuVasive Inc Earnings Call scheduled for 5:30 pm ET today Oct 30 2014
NuVasive Reports Third Quarter 2014 Financial Results and Increases Full Year Guidance Oct 30 2014
NUVASIVE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Oct 30 2014
NuVasive Reports Third Quarter 2014 Financial Results and Increases Full Year Guidance Oct 30 2014
Q3 2014 NuVasive Inc Earnings Release - After Market Close Oct 30 2014
NuVasive Announces Conference Call and Webcast of Third Quarter 2014 Results Oct 16 2014
NuVasive Announces Conference Call and Webcast of Third Quarter 2014 Results Oct 16 2014
NuVasive(R) Demonstrates Expanding EMEA Business at Eurospine 2014 With Surgeon Workshops and... Oct 01 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK